Friday, June 04, 2021

Avivagen Inc. (VIVXF)(VIV:CA)
Reports 2Q21 Results, Momentum Continues to Build

Avivagen Inc is a Canadian based company operating in the healthcare sector. It develops science-based, natural health products for animals. It develops and commercializes products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal’s own health defenses. Its product range includes OxC-beta, Vivamune health chews, Oximunol chewable tablets, and Carotenoid Oxidation products.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2Q21 Results. For the fiscal second quarter ended April 30th, Avivagen reported revenue of $159,614 and a net loss of $2.2 million, or a loss of $0.04 per share. This compares to revenue of $29,625 and a net loss of $1.4 million, or $0.03 per share, in the same period last year. We had forecast revenue of $550,000 and a net loss of $1.3 million, or a loss of $0.02 per share.


Timing is Everything.  As with most early stage revenue companies, the timing of orders can have an outsized impact on quarterly results, and we believe this is what happened in the quarter when comparing actual results to our projections. In the broader picture, the miss is not material, as long as we continue to see building momentum going forward. The bottom line miss is related to $665,203 …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.